Podcast 13 Sep 2024Targeting inflammation: A revolution in disease treatment NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies. Listen to our conversation with Halia Therapeutics about it. September 13, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 30 Jul 2024 Why is the immunology and inflammation market suddenly attracting a wave of investment? Discover why the immunology and inflammation market has recently been attracting a major wave of investment. July 30, 2024 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2024 The future of inflammatory bowel disease treatment: what is on the horizon? Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut. July 25, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 12 Oct 2023 Can immunometabolism-based therapies transform the way cancers and autoimmune diseases are treated? The immune system protects our bodies from foreign invaders, but sometimes, when it malfunctions, it can result in life-threatening autoimmune disorders. But what if the immune system could be regulated to counter these diseases? Immunometabolism, an emerging field in therapeutics, aims to rein in autoimmunity altogether. According to Neil Weir, chief executive officer (CEO) of […] October 12, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 15 Aug 2023 Can stem cell treatment repair damaged knees? Scientists’ fascination with amphibians like axolotls and newts, animals that are capable of scarlessly regrowing their limbs, sparked the idea of possibly replicating this in humans. Since 1958, when French oncologist Georges Mathe performed the first-ever stem cell transplantation – to save six nuclear researchers who were accidentally exposed to radiation – the technology has […] August 15, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2023 Biogen acquiring Reata Pharmaceuticals for $7.3B Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […] July 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 20 Jul 2023Beyond Biotech podcast 55: Inflammasomes This week on our podcast, we’re talking about inflammasome inhibitors with Alan Watt, CEO of NodThera. The company recently announced it is the first to show a reduction in neuroinflammation with an inflammasome inhibitor. NodThera announced positive initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects […] July 20, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 Immune memory research could lead to next generation of epigenetic drugs A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of memory cells, allowing for a fast activation of these cells. These features are altered in chronic inflammation diseases like asthma and could be important in […] July 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NodThera first to show reduction in neuroinflammation with inflammasome inhibitor NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF). NodThera is a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Alan […] July 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 NodThera announces positive inflammatory disease data NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a highly validated drug target that plays a pivotal role in controlling inflammatory diseases. The differentiated design characteristics of each candidate enabled them to penetrate different […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 May 2023 Five recent advancements in arthritis research over the past year Today, more than 350 million people across the world – and nearly a quarter of American adults – have arthritis. A condition characterized by pain, inflammation and stiffness in the joints – often owing to a hyperactive immune system causing the body to attack its own joint tissues, in the case of rheumatoid arthritis – […] May 22, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2023 Diagnosing inflammatory diseases with synthetic peptides Common inflammatory disorders such as ulcerative colitis and Crohn’s disease can be diagnosed or monitored by measuring the protein calprotectin in stool samples, while serum levels of calprotectin could be used to monitor the inflammation status in rheumatoid arthritis. Calprotectin concentrations in patient samples are typically determined using antibodies that bind and detect the protein, […] May 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email